This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gorschlüter, M. Articles by Schmidt-Wolf, I. G. H. Search for Related Content PubMed PubMed Citation Articles by Gorschlüter, M. Articles by Schmidt-Wolf, I. G. H.

Current Clinical and Laboratory Strategies to Augment the Efficacy of Immunotherapy in Multiple Myeloma¹

Department of Internal Medicine I, University of Bonn, 53105 Bonn, Germany

Multiple myeloma is still an incurable, lethal disease for the vast majority of patients. Myeloablative chemotherapy combined with autologous or allogeneic hematopoietic stem cell transplantation only partially met the great expectations initially set in its efficacy and is associated with a high level of toxicity. However, the considerable progress in understanding the biology of multiple myeloma led to the development of promising molecular therapies. Numerous immunotherapy-based approaches are currently evaluated in clinical trials. Moreover, remarkable progress has been achieved in gene therapy during the last decade, and the repertoire of gene transfer techniques can be expected to improve continuously. Gene transfer is increasingly applied in biological therapies in multiple myeloma. This article reviews the currently applied clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma and aims to define its perspectives in multimodality treatment of multiple myeloma.

This article has been cited by other articles:

				K. A. Keith, M. J. M. Hitchcock, W. A. Lee, A. Holy, and E. R. Kern Evaluation of Nucleoside Phosphonates and Their Analogs and Prodrugs for Inhibition of Orthopoxvirus Replication Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2193 - 2198. [Abstract] [Full Text] [PDF]